调节性B细胞扩增与1型固有淋巴细胞抑制揭示儿童狼疮性肾炎的免疫调节
这项前瞻性开放标签随机研究纳入60例活检证实的III/IV型儿童狼疮性肾炎患者,比较标准疗法联合贝利尤单抗与标准疗法的免疫调节差异。贝利尤单抗与调节性B细胞扩增、1型固有淋巴细胞减少及干扰素通路下调相关,并改善临床指标。
要点
- 贝利尤单抗联合标准疗法可扩增IL-10-producing Bregs并抑制循环及肾脏ILC1s。
- 贝利尤单抗组血清C3升高、抗dsDNA滴度下降、蛋白尿减少且激素暴露降低。
- 贝利尤单抗下调IFN刺激基因并降低IFN-γ、IL-17A、IL-10和BAFF水平,升高IL-35。
核心结论
- 儿童狼疮性肾炎中BAFF抑制与Breg功能增强和ILC1驱动的炎症抑制相关,从而再平衡固有与适应性免疫。
研究设计与样本
- 前瞻性开放标签随机研究,60例活检证实的III/IV型儿童狼疮性肾炎患者随机分为标准疗法组(霉酚酸酯和糖皮质激素,n=30)或标准疗法联合贝利尤单抗组(10 mg/kg静脉每4周一次共6个月,n=30)。
- 另设10名健康儿童和3例活检证实的微小病变病患者作为对照。
- 采用流式细胞术定量IL-10-producing Bregs和循环ILC1s;对3例临床指征的配对肾活检进行转录组和免疫荧光分析。
主要发现
- 贝利尤单抗与血清C3更大程度升高、抗dsDNA滴度降低、蛋白尿减少、SLEDAI-2K评分改善和糖皮质激素暴露减少相关。
- 贝利尤单抗扩增记忆B细胞和IL-10-producing CD19+CD5+及CD19+CD24hi+CD38hi+ Bregs,并增强对CD4+ T细胞增殖的抑制。
- 治疗减少循环和肾脏ILC1s,下调干扰素刺激基因并调节炎症通路。
- 血清细胞因子谱显示IFN-γ、IL-17A、IL-10和BAFF水平降低,同时IL-35升高。
- Bregs中芳香烃受体和STAT3的磷酸化部分恢复。
临床怎么用
- 在儿童III/IV型狼疮性肾炎中,贝利尤单抗联合标准疗法可能通过扩增Bregs和抑制ILC1s发挥免疫调节作用,并改善临床活动度指标。
局限性
- 研究为开放标签设计,样本量有限(每组30例),配对肾活检仅3例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its dysregulation contributes to the pathogenesis of lupus nephritis (LN). This study investigated whether BAFF-pathway inhibition alters the balance between regulatory B cells (Bregs) and type 1 innate lymphoid cells (ILC1s) in paediatric LN. METHODS: In this prospective, open-label randomised study, 60 paediatric patients with biopsy-confirmed class III/IV LN were randomised to standard therapy (mycophenolate mofetil and corticosteroids; n=30) or standard therapy plus the belimumab (10 mg/kg intravenously every 4 weeks for 6 months; n=30). Ten healthy children and three patients with biopsy-confirmed minimal change disease served as controls. Flow cytometry quantified IL-10-producing Bregs and circulating ILC1s. Clinically indicated paired renal biopsies (n=3) underwent transcriptomic and immunofluorescence analyses. RESULTS: Belimumab was associated with greater increases in serum C3, reductions in antidouble-stranded DNA titres, decreased proteinuria, improved Systemic Lupus Erythematosus Disease Activity Index 2000 scores and reduced corticosteroid exposure. Belimumab expanded memory B cells and IL-10-producing CD19+CD5+ and CD19+CD24hi+CD38hi+ Bregs, with enhanced suppression of CD4+ T cell proliferation. Treatment reduced circulating and renal ILC1s, downregulated interferon (IFN)-stimulated genes and modulated inflammatory pathways. Serum cytokine profiling showed decreased IFN-γ, interleukin (IL)-17A, IL-10 and BAFF levels, alongside increased IL-35. Phosphorylation of the aryl hydrocarbon receptor and signal transducer and activator of transcription 3 (STAT3) in Bregs was partially restored. CONCLUSIONS: BAFF inhibition in paediatric LN is associated with rebalancing of innate and adaptive immunity through enhancement of Breg function and suppression of ILC1-driven inflammation.
引用
- Lin CY, Chien JW, Lin KH, et al. Regulatory B cell expansion and type 1 innate lymphoid cell suppression characterise immune modulation in paediatric lupus nephritis. RMD Open. 2026. PMID: 42128531. doi:10.1136/rmdopen-2025-006492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。